Gaining Confidence in Predicting and Assessing Response to Cancer Immunotherapies

Gaining Confidence in Predicting and Assessing Response to Cancer Immunotherapies Co-Chairs, Tricia Cottrell, MD, PhD, and Lynette M. Sholl, MD, discuss immuno-oncology biomarkers in this CME/CC activity titled “Gaining Confidence in Predicting and Assessing Response to Cancer Immunotherapies: Practical Strategies for Biomarker Testing and Pathologic Response Assessment.” For the full presentation, downloadable Practice Aids, slides, and complete CME/CC information, and to apply for credit, please visit us at PeerView.com/GNU865. CME/CC credit will be available until April 13, 2024.

Gaining Confidence in Predicting and Assessing Response to Cancer Immunotherapies

Progress in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors

Drs. Wargo, Ariyan, & Postow discuss #Melanoma at #SSO2023 - https://bit.ly/40Kl2pl

Predictive biomarkers in gastroesophageal adenocarcinoma: tips and tricks

Maximizing the of Potential Current and Emerging Immunotherapies in Advanced Endometrial Cancer

Immunogenicity and Therapeutic Targeting of Recurrently Mutated "Public" Neoantigens

Why is standardisation so important for the Tumor Mutation Burden (TMB) biomarker?

A Look at Treatment Strategies for High-Risk AML Patients

AACR 2023 highlights on advances in the treatment of resected high-risk melanoma with Jeffrey Weber

Lung Cancer Biomarker Testing: Improving Turnaround from Presentation to Treatment

Importance of gaining real-world data following approvals of therapies

Pre-clinical models in brain cancer

Karine Breckpot, PhD | Leveraging mRNA Technology Workshop 2023

How Can Biomarkers Help With Lung Cancer Treatment?

ASH 2020: Khorana score falls short in onc study, factors predict VTE in cancer patients w/ COVID-19

Chemotherapy-free regimens in Ph+ ALL: where are we now and where are we headed?

Fall Asleep to Medicine | 3-Hour Sleep Documentary